Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Antiphospholipid Syndrome
•
General Rheumatology
•
APS
Do you avoid JAK inhibitors in patients with antiphospholipid antibodies and/or lupus anticoagulant given the potential risk of increased thromboembolic events with use of JAKi?
Related Questions
Is transdermal estrogen therapy safe for postmenopausal patients with positive antiphospholipid antibodies but no history of thrombosis or obstetric complications?
How do you approach recurrent migratory superficial thrombophlebitis in a patient with a negative malignancy workup and low-titer anticardiolipin antibodies?
Do you consider co-prescribing hormone therapy and anticoagulation in a patient with prior DVT and uncontrollable VSM uncontrolled by non-hormonal therapies?
Do you reduce the dose of hydroxychloroquine in patients with skin graying if they are not particularly bothered by this side effect?
Is there any value to IgG subclasses in assessing immune deficiency in a patient with normal IgG levels?
Are there specific conventional DMARDs and/or biologics that are contraindicated in patients with alpha-gal allergy?
How do you approach management of mucinous cysts associated with hand osteoarthritis?
How do you approach the treatment of patients with Ehlers-Danlos hypermobile type with chronic muscle spasms with minimal exertion?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
